The global acute myeloid leukemia (AML) therapeutics market is projected to grow from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, registering a compound annual growth rate (CAGR) of 9.2%, according to a new report by Fact.MR. The market is expected to create an absolute dollar opportunity of approximately USD 5.9 billion, expanding nearly 2.4 times its value over the forecast period. This growth reflects the increasing shift toward genomics-driven treatment strategies, targeted therapies, and personalized medicine approaches that are transforming the management of AML worldwide.
As healthcare providers increasingly adopt molecular diagnostics and mutation-based treatment selection, AML therapeutics are evolving from traditional chemotherapy-focused regimens toward highly individualized treatment pathways designed to improve patient outcomes and reduce disease recurrence. The report highlights that targeted therapies are expected to account for 36% of market share in 2026, making them the largest drug class segment within the AML therapeutics market. The increasing availability of mutation-specific drugs and novel targeted agents is expanding treatment options for patients with genetically defined AML subtypes.
By disease type, newly diagnosed AML is projected to hold 48% market share in 2026, as initial treatment regimens generate the highest therapy volumes. Hospitals remain the leading end-user segment, accounting for 55% of market demand, due to the intensive inpatient management required for AML treatment. Similarly, hospital pharmacies maintain a dominant position with 49% market share because of the complexity of AML therapies and the need for specialized handling and administration protocols.
One of the strongest growth drivers is the increasing availability of therapies for relapsed and refractory AML patients. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are expanding options for patients who previously had limited treatment alternatives. According to Shambhu Nath Jha, Principal Consultant at Fact.MR, "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability for diverse patient populations."
Regional markets display strong growth potential, with South Asia and East Asia emerging as high-growth regions due to expanding cancer care infrastructure and increasing access to molecular diagnostics. Among key countries, India is projected to grow at 11.8% CAGR, China at 10.9% CAGR, the United States at 8.7% CAGR, Germany at 7.9% CAGR, and Japan at 7.4% CAGR. North America continues to lead market revenues due to strong specialty pharmacy networks and high healthcare spending.
The global AML therapeutics market remains highly competitive, with leading pharmaceutical companies such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc. focusing on targeted therapies, mutation-specific treatments, and combination regimens. Industry participants are investing heavily in precision medicine, molecular diagnostics partnerships, clinical trials, and patient access programs to strengthen their competitive positioning and expand treatment accessibility.
Looking ahead, the future of the AML therapeutics market will be shaped by continued advances in precision oncology, molecular diagnostics, targeted therapies, and lower-intensity treatment regimens. As mutation testing becomes increasingly integrated into routine clinical practice, treatment decisions will become more personalized and data-driven. The growing availability of oral targeted therapies, relapse-focused drugs, and next-generation immuno-oncology approaches is expected to further expand treatment opportunities and improve patient outcomes. While challenges related to treatment costs, toxicity management, and reimbursement constraints remain, the long-term outlook for the AML therapeutics market remains highly positive as innovation continues to reshape the global hematology treatment landscape. For more details, the full report is available at Fact.MR's AML Therapeutics Report.
